title: The preoperative neutrophil-lymphocyte ratio predicts recurrence and survival among patients undergoing R0 resections of adenocarcinomas of the esophagogastric junction.
abstract: OBJECTIVE
  Elevated preoperative neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) predict survival rates among patients with several types of cancer. The current study sought to clarify whether NLR and PLR are clinically useful independent prognostic indicators of adenocarcinomas of the esophagogastric junction (AEG) among patients undergoing curative resections (i.e., R0 resections).
  
  
  METHODS
  A total of 327 patients who underwent R0 resections for AEG were enrolled in the study. Data concerning demographic parameters, laboratory analyses, histopathology, and survival time were collected and analyzed.
  
  
  RESULTS
  A total of 123 patients (37.6%) had elevated preoperative NLR (≥ 5). The median follow-up duration was 24.7 months (range = 2-39 months). NLR was significantly related to histology (P = 0.035), pTNM stage (P < 0.0001) and tumor recurrence (P = 0.022). Univariate analyses revealed that NLR were significantly associated with disease-free survival (DFS) and overall survival (OS; both P < 0.0001). Multivariable analyses revealed that elevated NLR independently predicted poorer DFS (hazard ratio [HR] = 2.551, P < 0.0001) and OS (HR = 2.743, P < 0.0001). However, PLR did not significantly predict DFS or OS.
  
  
  CONCLUSIONS
  The present study indicates that elevated preoperative NLR (≥ 5) is a useful marker of tumor recurrence and independently predicts poorer disease-free and overall survival among patients with AEG undergoing R0 resections.
authors.affiliation: Department of Surgical Oncology, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, P.R. China.
authors.forename: Dawei
authors.initials: D
authors.lastname: Yuan
authors.forename: Kun
authors.initials: K
authors.lastname: Zhu
authors.forename: Kang
authors.initials: K
authors.lastname: Li
authors.forename: Rong
authors.initials: R
authors.lastname: Yan
authors.forename: Yong
authors.initials: Y
authors.lastname: Jia
authors.forename: Chengxue
authors.initials: C
authors.lastname: Dang
mesh_terms: D000230:Adenocarcinoma / Q000097:blood / Q000401:mortality / Q000473:pathology / Q000628:therapy; D000328:Adult; D000368:Aged; D017024:Chemotherapy, Adjuvant; D018572:Disease-Free Survival; D004938:Esophageal Neoplasms / Q000097:blood / Q000401:mortality / Q000473:pathology / Q000628:therapy; D016629:Esophagectomy; D004943:Esophagogastric Junction; D005260:Female; D005743:Gastrectomy; D006801:Humans; D053208:Kaplan-Meier Estimate; D018655:Lymphocyte Count; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009504:Neutrophils; D010976:Platelet Count; D057234:Preoperative Period; D011379:Prognosis; D012189:Retrospective Studies; D013274:Stomach Neoplasms / Q000097:blood / Q000401:mortality / Q000473:pathology / Q000628:therapy
keywords: adenocarcinomas of the esophagogastric junction; neutrophil-lymphocyte ratio; platelet-lymphocyte ratio; recurrence, prognosis